UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS

JNCI : Journal of the National Cancer Institute, 2011-03, Vol.103 (6), p.478-488

2011

Volltextzugriff (PDF)

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1677-1683

2010

Volltextzugriff (PDF)

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

The lancet oncology, 2010-10, Vol.11 (10), p.927-933

2010

Volltextzugriff (PDF)

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

Journal of clinical oncology, 2012-04, Vol.30 (12), p.1268-1273

2012

Volltextzugriff (PDF)

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

The Lancet (British edition), 2013-05, Vol.381 (9880), p.1827-1834

2013

Volltextzugriff (PDF)

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2466-2473

2009

Volltextzugriff (PDF)

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

Journal of clinical oncology, 2006-08, Vol.24 (23), p.3726-3734

2006

Volltextzugriff (PDF)

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2327-2333

2011

Volltextzugriff (PDF)

Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

JNCI : Journal of the National Cancer Institute, 2005-11, Vol.97 (22), p.1652-1662

2005

Volltextzugriff (PDF)

Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection

Journal of surgical oncology, 2010-08, Vol.102 (2), p.111-118

2010

Volltextzugriff (PDF)

Validation studies for models projecting the risk of invasive and total breast cancer incidence

JNCI : Journal of the National Cancer Institute, 1999-09, Vol.91 (18), p.1541-1548

1999

Volltextzugriff (PDF)

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

JNCI : Journal of the National Cancer Institute, 1998-09, Vol.90 (18), p.1371-1388

1998

Volltextzugriff (PDF)

Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women

JNCI : Journal of the National Cancer Institute, 2007-12, Vol.99 (23), p.1782-1792

2007

Volltextzugriff (PDF)

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

The New England journal of medicine, 2010-06, Vol.362 (22), p.2053-2065

2010

Volltextzugriff (PDF)

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3197-3204

2013

Volltextzugriff (PDF)

Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System

Journal of clinical oncology, 2007-05, Vol.25 (15), p.2127-2132

2007

Volltextzugriff (PDF)

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors

Journal of clinical oncology, 2011-11, Vol.29 (33), p.4365-4372

2011

Volltextzugriff (PDF)

Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women

JNCI : Journal of the National Cancer Institute, 2011-06, Vol.103 (12), p.951-961

2011

Volltextzugriff (PDF)

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

JNCI : Journal of the National Cancer Institute, 2019-08, Vol.111 (8), p.867-871

2019

Volltextzugriff (PDF)

Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer

JNCI : Journal of the National Cancer Institute, 1999-11, Vol.91 (21), p.1829-1846

1999

Volltextzugriff (PDF)

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

Cancer prevention research (Philadelphia, Pa.), 2010-06, Vol.3 (6), p.696-706

2010

Volltextzugriff (PDF)

Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant Trials

Annals of surgical oncology, 2010-04, Vol.17 (4), p.959-966

2010

Volltextzugriff (PDF)

1 – 25 von 1.806

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.609)
Mit Volltextzugriff
(1.489)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.100)
Life Sciences & Biomedicine
(914)
Humans
(726)
Female
(498)
Biological And Medical Sciences
(454)
Medical Sciences
(366)
Male
(362)
Middle Aged
(306)
Adult
(257)
Animals
(238)
Aged
(221)
Oncology
(134)
Physical Sciences
(122)
Pharmacology. Drug Treatments
(120)
Technology
(107)
Fundamental And Applied Biological Sciences. Psychology
(105)
Treatment Outcome
(100)
Tumors
(98)
Pharmacology & Pharmacy
(87)
Risk Factors
(87)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection

Validation studies for models projecting the risk of invasive and total breast cancer incidence

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors

Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American Women

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant Trials

Suchergebnisse filtern